@article{219e14bbe41a4d02935f6601ca028209,
title = "Switching from ranibizumab to aflibercept in choroidal neovascularization secondary to angioid streaks",
abstract = "Purpose: To evaluate the efficacy of switching from intravitreal ranibizumab to intravitreal aflibercept in choroidal neovascularization secondary to angioid streaks. Design: Multicenter retrospective interventional case series. Methods: Patients previously treated with intravitreal ranibizumab with at least 12-month follow-up (M12) after switching (M0) to intravitreal aflibercept. Switch to intravitreal aflibercept was decided in cases of refractory or recurrent choroidal neovascularization. Primary endpoint: Change of best-corrected visual acuity using the Early Treatment Diabetic Retinopathy Study letters. Secondary endpoints: Mean change of central macular thickness, absence of intraretinal/subretinal fluid on spectral domain optical coherence tomography and the percentage of eyes with absence of leakage on fluorescein angiography. Results: Fourteen eyes of 13 patients were included. Mean best-corrected visual acuity was 65.0 ± 21.03 letters at M0 and 63.5 ± 17.30 letters at M12 (p = 0.5). Secondary endpoints: Mean central macular thickness was 344 ± 194.65 µm at M0 and 268 ± 79.97 µm at M12 (p = 0.008). Absence of intraretinal/subretinal fluid was observed in 71%. Fluorescein angiography (nine eyes) showed absence of leakage in 77% (seven eyes). Conclusion: Switching from intravitreal ranibizumab to intravitreal aflibercept represents a therapeutic option in patients with refractory or recurrent choroidal neovascularization secondary to angioid streaks.",
keywords = "Aflibercept, angioid streaks, anti-vascular endothelium growth factor therapy, choroidal neovascularization, fluorescein angiography, ranibizumab, spectral domain optical coherence tomography, switch",
author = "Rim Sekfali and G{\'e}rard Mimoun and Cohen, {Salomon Yves} and Giuseppe Querques and Francesco Bandello and Riccardo Sacconi and Souied, {Eric H.} and Vittorio Capuano",
note = "Funding Information: R.S., G.M., R.S., and V.C.: none. S.Y.C. is consultant for Alcon (Fort Worth, Texas, USA), Allergan Inc (Irvine, California, USA), Bayer Shering-Pharma (Berlin, Germany), Novartis (Basel, Switzerland), Farmila-Thea (Clermont-Ferrand, France), G.Q. is a consultant for Alimera Sciences (Alpharetta, Georgia, USA), Allergan Inc (Irvine, California, USA), Bayer Shering-Pharma (Berlin, Germany), Heidelberg (Germany), Novartis (Basel, Switzerland), Sandoz (Berlin, Germany), Zeiss (Dublin, USA). F.B. is a consultant for Alcon (Fort Worth, Texas, USA), Alimera Sciences (Alpharetta, Georgia, USA), Allergan Inc (Irvine, California, USA), Farmila-Thea (Clermont-Ferrand, France), Bayer Shering-Pharma (Berlin, Germany), Bausch and Lomb (Rochester, New York, USA), Genentech (San Francisco, California, USA), Hoffmann-La-Roche (Basel, Switzerland), Novagali Pharma (?vry, France), Novartis (Basel, Switzerland), Sanofi-Aventis (Paris, France), Thrombogenics (Heverlee, Belgium), Zeiss (Dublin, USA). E.H.S. is a consultant for Alimera Sciences (Alpharetta, Georgia, USA), Allergan Inc (Irvine, California, USA), Farmila-Thea (Clermont-Ferrand, France), Bayer Shering-Pharma (Berlin, Germany), Bausch and Lomb (Rochester, New York, USA), Genentech (San Francisco, California, USA), Heidelberg (Germany), Novartis (Basel, Switzerland). The author(s) received no financial support for the research, authorship, and/or publication of this article. Publisher Copyright: {\textcopyright} The Author(s) 2019. Copyright: Copyright 2020 Elsevier B.V., All rights reserved.",
year = "2020",
month = may,
day = "1",
doi = "10.1177/1120672119838133",
language = "English",
volume = "30",
pages = "550--556",
journal = "European Journal of Ophthalmology",
issn = "1120-6721",
publisher = "Wichtig Publishing",
number = "3",
}